Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

In this cohort study, most patients with overweight or obesity discontinued glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy within 1 year, but those without type 2 diabetes had higher ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 ...

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

A RECENT population-based analysis has highlighted potential behavioural side effects associated with Glucagon-like peptide 1 ...